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Information in practice
Information needed to decide about cardiovascular
treatment in primary care
John Robson
Abstract
There is growing consensus that treatment of
cardiovascular risks should be based on multiple
rather than single factors and on absolute rather than
relative risks. Thresholds for treatment should reflect
the level of absolute risk at which the benefits and
hazards of treating outweigh the benefits and hazards
of not treating. Once a decision has been made to
initiate a treatment programme, clinicians need to
know the patient’s absolute risk. At this level of risk,
do the benefits of treatment outweigh the hazards?
Given this information, which treatment option does
the patient prefer? Using cardiovascular disease as an
example, I review some measures that assist decision
making in primary care. Practice guidelines should
routinely include accessible presentation of treatment
outcomes on benefit, hazard, and costs for a range of
absolute risks. These measures enable patients and
their doctors to weigh the pros and cons of treatment
in their particular circumstances.
Introduction
There are three main sources of information guiding
decisions about cardiovascular treatment. Cohort stud›
ies provide information on multiple risk factors and
subsequent cardiovascular events, so that a person’s
absolute risk may be estimated from a score.1 Risk
might be considered high if the chance of death or dis›
ease from a major coronary event exceeded 6% a year
(60% in 10 years). However, risk alone reveals nothing
about the advisability of drug treatment, and, although
cardiovascular risk scores have been available for more
than 20 years, uncertainty about their role has
hindered integration into routine clinical practice.2 3
The second source, based on clinical trials, yields at a
particular level of risk a variety of treatment outcomes,
including the “number needed to treat,”4 years of life
gained, adverse events, and costs.5 The third source of
information is the person to be treated, who, given an
informed choice of treatment outcomes, can indicate
his or her preference.6
Assessing cardiovascular risk
Cardiovascular risk scores were originally designed to
facilitate behavioural change by communicating the
degree of risk to clinicians and patients. More recently,
they have been used to target treatment more
effectively, because prediction of risk is improved when
based on multiple rather than single risk factors. Rela›
tive risk scores such as the Dundee score, may have a
continuing role in behavioural change, particularly
among lower risk groups at younger ages.7 However,
relative risk has been criticised as a method of allocat›
ing treatment, and absolute risk (from which relative
risk may be derived) is preferable.2 8
The main coronary risk scores are based on data
from the American Framingham study,9 the British
regional heart study,10 and Scottish survey and British
trial data (Dundee score).7 All were specifically devised
to influence primary care doctors.11 12 The Framing›
ham study has the advantages of longer follow up over
a wider age range for both sexes and is expressed as
absolute risk.1 In addition, it has shown that the ratio of
serum total cholesterol concentration to high density
lipoprotein cholesterol is a considerably better predic›
tor than total cholesterol concentration alone. Five or
10 year risks may be estimated and scores tabulated by
age so that the effects of multiple risk factors can be
compared over time.13 It has the disadvantage that it is
based on an American population. Scores are also
available for the risk of stroke.12 14 15
Recent cardiovascular guidelines in Europe13 and
New Zealand8 adapted the Framingham data and
incorporated other risk factors such as obesity and
family history. This has made the risk equations more
user friendly and has taken some account of specialists
in hypertension, who variably recommend treatment at
diastolic thresholds of 90, 95, and 100 mm Hg16 even
though data from both Framingham and the Medical
Research Council indicate that systolic pressure is a
considerably better predictor of stroke.14 17
Because prediction depends on the prevalence of
the condition, none of the risk scores has a high
predictive value. The scores overestimate risk, and only
60% of those subjects at highest risk (in the top 10% of
the risk distribution) will actually have a coronary event
within the next 10 years. Prediction is considerably
worse at younger ages and lower levels of risk. Factors
not included in the score, such as family history of
cardiovascular disease (first degree relative aged under
55) or obesity, may mean that risks are higher than
predicted. Social class and ethnic group may also be
relevant. Nevertheless, for all their limitations, multiple
risk scores are the best available tools for predicting
risk and are superior to any one factor alone.
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The adoption of absolute, rather than relative, risk
as the criterion for treatment inevitably prioritises
older age groups. On this basis, healthy men aged
under 50 years with a serum cholesterol concentration
of ≤ 9 mmol/l do not require drug treatment. Although
their relative risk is high compared with their peers
with a serum cholesterol concentration of 5 mmol/l,
even if they smoke and have raised blood pressure they
are unlikely to reach a coronary event rate of 3% a year,
the threshold at which the Sheffield group considers
treatment appropriate.18›20 Advice to stop smoking,
exercise, and improve their diet remains the mainstay
of intervention.
Treatment thresholds and treatment
outcomes
Once a person’s absolute risk has been estimated how
is the threshold at which treatment is indicated to be
decided? More information is needed, and patients and
their doctors require summaries of the hazards,
benefits, and costs of treatment.
Risk scores describe the level, distribution, and
relative importance of different factors but give no
information on the outcomes resulting from treat›
ment. The final choice of treatment is affected by the
choice of outcome, cause of death or disease, deaths
prevented or number needed to treat, years of life lost
or gained, adverse events or indicators of quality of life,
and cost. Should treatment of raised blood pressure
depend on the risk of stroke or the risk of heart attack
or both? Other outcomes may be decisive factors in
treatment. The impact of diabetes on risk of stroke is
modest, but the impact of raised blood pressure on
diabetic renal disease is considerable.
Benefits of treatment
The manner in which benefits are expressed is particu›
larly important. Expressing values as numbers needed
to treat gives equal weight to the risk of dying from a
heart attack at the age of 75 as at age 40. However, if
years of life gained rather than numbers of deaths were
used as the outcome, intervention would include more
younger people and fewer older people.21 Both
measures are useful, as each expresses a different com›
ponent of outcome.22 An important gain in mean life
expectancy would be about 60 days. This is not so small
a gain as it seems, as it is averaged over all people
receiving treatment.23 For example, if all cancer were
eradicated the mean gain in life expectancy would be
only one year, although for the people who would oth›
erwise have developed cancer the gain would be meas›
ured in decades.
The format in which these outcomes are presented
may influence choice of treatment. Thus, presenting
results in terms of years of life gained may lead to dif›
ferent treatments being preferred than when results
are given as numbers needed to treat,24 and relative risk
may result in lower treatment thresholds than absolute
risk.25
The number needed to treat to prevent one event
or death is the reciprocal of the absolute difference in
outcome between the treatment and control groups in
a clinical trial26 and is a measure of the absolute efficacy
of treatment. Assuming a 30% reduction in coronary
heart disease as a result of treatment with “statins”
(hydroxymethylglutaryl coenzyme A reductase inhibi›
tors), 1332 people at low risk (with an annual coronary
event rate of 0.05%) would require treatment for five
years to prevent one coronary event. In contrast, 20
people would need treatment for five years to prevent
one event if their annual risk was 3%. Table 1 shows the
number needed to treat for different levels of risk.
Adverse effects and quality of life
There is most uncertainty about treating the many
people at intermediate risk, rather than the smaller
group at high risk who have most to gain from
treatment. Small changes in the threshold of treatment
in the intermediate range can turn large numbers of
people into lifelong patients. Clinicians should require
a high level of confidence in the extent of the benefits
and hazards to convince them that treatment of such
patients is worth while because small but serious risks
applied to large numbers can transform gains in one
area into a net loss.27 If recommendations are uncertain
or contradictory, patients and doctors require more
information, accessibly presented, about the hazards
and benefits of treatment so that they can make their
own judgments.
Quality of life may be valued more than years of
life, and the adverse effects of treatment may be
decisive in the choice of treatment.28 In the Medical
Research Council trial of treatment of mild hyperten›
sion, for each cardiovascular event prevented, 33 men
experienced adverse reactions (impotence and fatigue
being prominent) and 20% stopped treatment as a
result.17 Although adverse effects of treatment can be
incorporated in the concept of years of quality adjusted
life gained,21 the subjective perception of hazards can
have profound effects on the choice of both patients
and public.29 This is shown by the unpopularity of pro›
static surgery for urinary symptoms: after the risks and
benefits of different treatments had been explained, the
degree of inconvenience caused by the treatment and
concern about impotence were the most important
predictors of choice, and only 20% of men with severe
symptoms opted for surgery.28 Given an informed
choice, patients often express preferences that are dif›
ferent from those of their doctors or peers.30 31
Decision analysis is able to concurrently assess the
impact of multiple components, including quality of
life, on treatment options,32›34 but many questions
remain. What is a reasonable number needed to treat
or cost per year of life gained? How sensitive is the
analysis to alterations in parameters? Do the results
need further qualification for population subgroups?
Table 1 Number of patients who would need to be treated with
a “statin” for five years to prevent one coronary event by annual
risk of coronary event (assuming treatment reduces number of
coronary events by 30%)
Annual risk of event (%) Number needed to treat
0.05 1332
0.1 666
0.5 133
1 66
2 34
3 20
5 14
7 10
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Cost and workload
The monetary cost of different treatments may be
compared through cost›effectiveness analysis. Because
gains are often fairly small, the conclusions of such
analyses can be highly sensitive to minor changes in
parameters, including drug costs.35 While this may not
be a problem when comparing two treatments under
similar conditions or the incremental gains of extend›
ing a programme, it is a major issue when working out
the basic costs of a programme for treating mild
hypertension.36 In addition, equity is omitted as a con›
sideration in most analyses,37 although there is no rea›
son in principle why it should not be incorporated.38
Policy decisions may be influenced by both
workload and the overall cost of a programme. These
are determined by the size of the target population,
and any new programme identifying treatment for
more than 2% of the population has major
implications for workload in primary care.2 At a policy
level, consideration should be given to whether greater
benefit may be obtained at the same cost from some
other intervention.
Accessible summaries of treatment
outcomes
These aids to decision making offer no tablets of stone.
Instead, they provide estimates of the limits of
uncertainty and a means to compare the relative value
of different options. The presentation of a range of
outcomes may not solve the problem, but it does estab›
lish a common currency in which options are explicit
and decisions may be shared.23 I discuss the use of such
measures in the current debates on the treatment of
raised blood pressure and cholesterol.
Managing hypertension
While the New Zealand and European cardiovascular
guidelines usefully summarise cardiovascular risk, nei›
ther provide an accessible summary of the numbers
needed to treat, years of life gained, adverse event rates,
costs, or workload at each level of absolute risk. Doubts
remain about treating mild hypertension at younger
ages. For example, 400 men aged 52 with systolic blood
pressure < 150 mm Hg would require treatment for five
years to prevent one stroke. This number falls to 250
for systolic pressure of 150›169 mm Hg and to 100 for
systolic pressure of 170›199 mm Hg.39 40 Lifetime treat›
ment is estimated to add an average of 30 to 64 days to
life expectancy; at 1995 prices, the cost ranged from
£14 000 to £82 000 for men (greatest in the youngest
patients) and from £28 000 to £252 000 for women for
each quality adjusted life year gained.41
Patients and doctors need easy access to such data
to inform their decisions. Table 2 shows a summary of
outcome measures that might be included in future
guidelines. It is not until annual cardiovascular risk is
1.5% or more that the benefits of treating raised blood
pressure begin to become clear.8 While a national
strategy to reduce dietary salt and obesity would have
considerably more impact than drug treatment, and at
considerably less cost,1 42 patients and their doctors
must, for now, rely on evidence of this kind to inform
their choice of treatment.
Managing serum cholesterol
The management of serum cholesterol presents
greater uncertainty, although this is now changing for
high risk patients. For people with heart disease and
serum cholesterol above 6.5 mmol/l, and possibly at
lower levels, treatment with “statins” to reduce
cholesterol confers benefit.19 43 For people without
heart disease at lower absolute risk, recommendations
for drug treatment based solely on their relative risk
due to raised cholesterol have been controversial. The
European Atherosclerosis Group13 and a Sheffield
group18 20 have attempted to resolve the dilemma by
recommending that treatment be based on absolute
risk calculated with data from the Framingham study.
Even with these more conservative guidelines, the
number of people for whom treatment is recom›
mended is substantially higher than reviews of
previous trials seem to warrant. For people without
pre›existing heart disease, adverse effects of treatment
may be decisive, and further large scale trials are neces›
sary to establish lower limits for treatment.27 44
The west of Scotland study indicates that, among
healthy men with an average serum cholesterol
concentration of 7 mmol/l and annual coronary event
risk of 1.5%, 200 people would require treatment for
five years to prevent one coronary death and 40 would
require treatment for this period to prevent one
coronary event.45 Table 3 compares the results of this
study with those of the Scandinavian simvastatin
survival study.19 Again, this simple summary of
Table 2 Summary of outcomes of treatment to reduce blood pressure in men aged 50
with raised blood pressure at different levels of cardiovascular risk. (Source of data:
MRC Working Party,17 Kawachi et al 41)
Annual risk of stroke or coronary
event
0.5% 1.0% 1.5%
Systolic blood pressure (mm Hg) 150 160 180
Number needed to treat for five years to prevent one stroke 400 250 100
Mean benefit (gain in days of quality adjusted life) 30 45 65
No of patients experiencing adverse events per stroke prevented 80 50 20
Cost per quality adjusted life year gained (£)* 32 000 21 000 14 000
*At prices in 1995.
Table 3 Summary of outcomes of treatment with “statins” to
reduce serum cholesterol concentration in people with and
without pre›existing heart disease (Source of data:
Scandinavian Simvastatin Survival Study Group,19 Shepherd
et al,45 Yusuf et al 46)
Pre›existing heart disease
Yes* No†
Annual risk of coronary event (%) 6 1.5
Mean serum cholesterol concentration
(mmol/l)
6.7 7.0
Number needed to treat for five years:
To prevent one coronary death 28 200
To prevent one coronary event 15 40
No of patients experiencing adverse effects
per coronary death prevented
2‡ 3
Cost per year of life gained (£)§ 17 000 Not available
Proportion of population proposed for
treatment (%)
0.3 20
*Scandinavian study of men and women with mean age 58 years.
†West of Scotland study of men with mean age 55 years.
‡There was also a non›significant 12% excess of non›coronary deaths among
women.
§At prices in 1995.
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treatment outcomes would enhance future guidelines,
although gains in life years were not available at the
time, nor were costs in the Scandinavian study. Even at
the low levels of adverse reaction reported, for every
one person gaining from prevention of coronary
death, two or three people would experience adverse
effects from treatment. It is in these areas of
uncertainty that there is the greatest need for
accessible presentation of available data.
Conclusion
Absolute multiple risk scores usefully summarise risk
and are better predictors than any single factor.
However, risk is only half the story. Accessible presen›
tation of numbers needed to treat, years of life gained,
adverse events, cost, and workload is also needed for
shared decision making, enabling patients and their
clinicians to weigh the pros and cons of treatment in
their particular circumstances. These measures should
be routinely included in management guidelines. Deci›
sion tools may only approximate to the truth, but pre›
senting a range of treatment outcomes establishes a
common currency for informed choice. Placing finite
limits on uncertainty is the best guarantee that
treatment will be optimal and appropriate.47
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Women’s need for information before attending genetic
counselling for familial breast or ovarian cancer: a
questionnaire, interview, and observational study
N Hallowell, F Murton, H Statham, J M Green, M P M Richards
Abstract
Objectives: To describe women’s information needs
prior to genetic counselling for familial breast or
ovarian cancer.
Design: Prospective study including semistructured
telephone interviews before genetic counselling,
observations of consultations, completion of postal
questionnaires, and face›to face interviews within two
months of counselling.
Subjects: 46 women attending genetic counselling for
familial breast or ovarian cancer.
Main outcome measures: Subjects’ understanding of
process and content of genetic counselling before
attending and attitudes about their preparation for
the counselling session.
Results: Although all women interviewed before the
clinic expected to discuss their risk of developing
cancer and risk management options, there was
evidence of a lack of knowledge about the process
and content of genetic counselling; 17 (37%) women
said they did not know what else would happen. Most
women interviewed after counselling viewed it
positively, but 26 (65%) felt they had been
inadequately prepared and 11 (28%) felt that their
lack of preparation meant that they could not be
given an accurate estimation of their risk of cancer.
Conclusions: Some women felt that they did not
obtain optimum benefit from genetic counselling
because they were inadequately prepared for it. We
suggest that cancer family history clinics should
provide women with written information about the
process and content of genetic counselling before
their clinic attendance.
Introduction
As the genetic basis for common multifactorial
disorders becomes increasingly recognised there will
be increasing demand for genetic counselling. It is
therefore important to determine efficient ways of pro›
viding this service. Recent studies have looked at the
provision of information during genetic consultations1
and counsellees’ expectations before attending cancer
family history clinics.2 Using data obtained during a
prospective study of genetic counselling for breast or
ovarian cancer,3 we present suggestions for the use of
written information by family history clinics.
Subjects and methods
Subjects
We recruited subjects from Cambridge Cancer Family
History Clinic. After excluding those who had had
breast or ovarian cancer or who had previously
attended genetic counselling, we invited all women
referred between February 1994 and February 1995 to
take part. We approached 59 eligible women and
recruited 46. The participants were aged 22›59 years
(mean 40 years), and table 1 shows details of their fam›
ily history of cancer.
Data collection
We collected data from interviews, observations, and
questionnaires (see table 2). We recorded and tran›
scribed the interviews and consultations with the wom›
en’s consent. The study was approved by Cambridge
Local Research Ethics Committee.
Data analysis
We coded the interview transcripts using the computer
package Atlas›ti (Thomas Muhr, Berlin). Categories
were based on the interview questions and recurring
themes identified.4 The consultations were coded as
agenda setting, family history, epidemiological, genetic,
risk and screening information, surgery, hormone
therapy, DNA testing, and other. We analysed the ques›
tionnaire data with the statistical package spss.
Clinic procedures
Before their appointment, counsellees were sent a
form asking them to list affected relatives and their
This article and entire
section are available
on the BMJ web site.
Table 2 Timing and method of data collection from 46 women attending genetic counselling for familial cancer
Timing Method Data collected No of women
1 Week before consultation Semistructured telephone interview Expectations of counselling, perception of risk, details of referral 46
Consultation Observation Audio tapes of consultation 46
2›4 Weeks after consultation Postal questionnaire Attitudes to counselling, presentation of risk information, and DNA
testing
43
4›8 Weeks after consultation Semistructured face to face interview Attitudes to counselling, recall and understanding of information 40
Table 1 Family history of cancer of 46 women attending genetic
counselling
Type of familial cancer
No (%) of
women
Breast and ovarian cancer 10 (22)
Breast cancer only 18 (39)
Ovarian cancer only 16 (35)
Breast cancer and uterine or stomach cancer 2 (4)
Information in practice
Centre for Family
Research, Faculty of
Social and Political
Sciences, University
of Cambridge,
Cambridge
CB2 3RF
N Hallowell,
research associate
F Murton,
research associate
H Statham,
senior research
associate
M P M Richards,
reader in human
development
Department of
Midwifery Studies,
University of Leeds,
Leeds LS2 9LN
J M Green,
senior lecturer
Correspondence to:
Dr Hallowell.
BMJ 1997;314:281–3
281BMJ VOLUME 314 25 JANUARY 1997
type of cancer, relationship to counsellee, date of birth,
diagnosis and death, and details of hospitals where
they had been treated. A few women contacted the
clinic for further information and were told the
approximate duration of the consultation, that they
would not have a physical examination, and to write
down questions for discussion. No physical examina›
tions were performed during the consultations,
although some counsellees were asked to donate blood
for research purposes. Women were referred elsewhere
for breast and ovarian screening.
Results
Preclinic expectations
Before attending the clinic, participants were asked
“What do you hope to get out of the appointment?” All
expected to discuss their family history, their own and
other family members’ risks, and options for risk man›
agement. However, there was widespread uncertainty
about what else would occur, and 17 (37%) women said
that they had no idea about what else to expect.
Unfamiliarity with the process and content of
counselling inhibited counsellees from formulating
questions in advance. In answer to the question “Have
you any particular questions you want to ask the coun›
sellor?” 13 (28%) women said they had not prepared
questions as they envisaged their role in the con›
sultation as passive—they assumed that the counsellor
would question them and make recommendations.
Consultations
The counsellors tried to establish the counsellees’
expectations at the beginning of the consultations by
asking them why they had been referred and what they
expected. However, only one counsellee revealed her
uncertainty at this point. The counsellees’ lack of
preparation became more apparent when the family
history was taken as many became embarrassed when
they were unable to provide information.
Responses to postclinic questionnaire
Despite the women’s high level of satisfaction with the
consultation (see table 3), 12/43 (28%) said that they
had been disappointed by some aspect of genetic
counselling (for example, not having DNA testing or
not being given enough information).
Responses to postclinic interview
Although 16 (40%) women said that they had not
known what to expect, most participants regarded
counselling as a positive experience. However, only 14
(35%) women reported feeling adequately prepared—
“If there was anything I could change, it would be to let
somebody know earlier what it really entails. Because I
didn’t know what to expect. I didn’t know...they’re going
to talk to you about your family history. They are going
to relate your family history to histories that they
already have.”
Eleven (28%) women said that they would have
liked to have known beforehand exactly what details of
family history were needed. Some had not realised the
importance of male or distant relatives or that they
would be asked for health details of family members
not affected with cancer. They worried that the gaps in
their information meant that they were unable to
obtain an accurate estimate of risk, despite the fact that
the counsellors always stressed the provisional nature
of estimating risk.
Two (5%) women wished that they had been
advised to prepare questions, as they had not realised
that counselling was a two way process. Four (10%)
women who received a qualitative risk estimate said it
would have been helpful if they had been given a
numerical risk, and two were not aware that this was
possible.
Six (15%) women said the consultation did not
match up to their expectations: four had thought that
they would have a blood test (it was unclear whether
they envisaged this as diagnostic or DNA testing), and
two had expected to have a clinical examination or
screening—“I had no idea what was going to happen. I
thought maybe I was going to have a full examin›
ation.... I’ve never had a mammogram, and I thought
maybe that would happen.”
Some women said their anxiety about what would
occur or the information they might receive had
affected the way they approached the consultation—“I
was in such a state when I got there. [My friend] and I
sat in the car counting down.... And I’m saying to [my
Table 3 Response of 42 women who attended genetic
counselling for familial breast or ovarian cancer to the question
“Overall, how satisfied are you with your experience of genetic
counselling?”
Degree of satisfaction No (%) of women
5 (very satisfied) 23 (55)
4 12 (26)
3 5 (11)
2 4 (9)
1 0
0 (not at all satisfied) 0
Key messages
x Genetic services are coming under increasing
pressure as more women are referred for
genetic counselling because of a family history
of breast or ovarian cancer
x We interviewed women before and after they
attended genetic counselling to find their views
of the process
x All women interviewed before the clinic
expected to discuss their risk of developing
cancer and options for risk management, but
many said they did not know what else would
happen
x Women interviewed after counselling generally
viewed it positively, but most felt they had been
inadequately prepared and some felt that their
lack of preparation meant that they could not
get an accurate estimation of their risk of cancer
x Women need information about genetic
counselling before they attend the clinic so that
they are adequately prepared, and a written
leaflet describing the process and explaining
some basic genetic facts could be a cost effective
means of providing this
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friend], ‘You listen for me because I can’t take it in....’
And both of us were just like messes in the car.... Just
before I went in for the appointment, my mind just
went blank.”
Discussion
Our subjects reported a high degree of satisfaction
with counselling, but uncertainty about what the
consultation entailed meant that a substantial
proportion did not formulate questions in advance.
Indeed, only 35% of the women considered themselves
adequately prepared. Most knew that they wanted
information about their risk of cancer and 38 (83%)
received a quantitative risk estimate, but 11 (28%) felt
that their lack of preparation meant that they could not
obtain a definitive risk estimate. These findings suggest
that counsellees would benefit from receiving infor›
mation about the process and content of genetic
consultations before they attend. A cost effective way to
implement this suggestion would be to send counsel›
lees a leaflet describing the practice of genetic counsel›
ling in a particular clinic and including some
background information about familial breast and
ovarian cancer (see box).
Many studies report that patients often prefer written
to oral information5 and that receiving written
information before treatment reduces anxiety,6 is
reassuring,7 and increases patient satisfaction.6 8 We
believe that the service delivery in cancer family history
clinics could be improved by the use of written
information, as it would not only allay anxiety about
the forthcoming consultation but also focus counsel›
lees’ concerns and ensure they bring the relevant
information. This may reduce the need for clinics to
contact counsellees for further information and the
number of requests for follow up consultations.
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A PATIENT WHO CHANGED MY PRACTICE
The question that made all the difference
A 43 year old woman presented at my outpatient clinic
with a moderate depressive disorder associated with the
break up of a relationship. She had become progressively
more withdrawn and isolated. Further questioning revealed
that she had for many years avoided going out on her own
and this included shopping and going on public transport.
As part of her treatment I planned to use a
behavioural model and started to explain to her about
keeping a diary about her mood and activities. She fully
agreed to this and had nodded in agreement as I wrote
down examples. But as she came to leave and I was writing
down the time and date of her next appointment,
something in the way she looked at the card made me
hesitate and then ask, “Can you read and write?”
She blushed, hesitated, and then hesitatingly admitted
that she could not.
Following this revelation we were able to get her help,
and when she could read and write she could venture to
the shops and on public transport as she could now read
the labels, directions, and bus numbers.
I now check that all my patients can read and write.
Sarah Beesley is a lecturer in psychological medicine in
Glasgow
Suggested content of information
leaflet about genetic counselling
Description of process of genetic counselling as practised in
clinic— This should inform counsellees about what will
occur during their consultation: that their family
health history will be discussed, whether blood may be
taken, and whether screening or physical examination
may be performed. It should also emphasise that
counselling is a two way exchange and encourage
counsellees to prepare questions for the counsellor.
An indication of whether it would be appropriate for a
partner or close relative to attend the consultation
would be helpful
Description of content of genetic discussions— This should
outline the topics that may be discussed during the
consultation: family history, risk assessment, and
options for risk management for both counsellee and
relatives. A list of all the details of the family history
that the counsellee needs to bring to the consultation
should be included. It should be emphasised that
information about all known blood relatives, male and
female and not just those affected by cancer, may be
helpful
Background information— This should include brief
epidemiological facts about the cancers (for example,
the population risk of breast cancer is 1 in 12 and
about 5% of cases of breast cancer are caused by an
inherited predisposition), a simplified illustration of
autosomal dominant inheritance, and a brief
description of current research into cancer genes and
the implications for DNA testing
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Netlines
Medline on the web
x One of the best biomedical sites on the web has just got
better. The United States National Center for Biotechnology
Information at the National Library of Medicine has for
some time offered free access to a subset of Medline dealing
with genetics as part of its Entrez series of interlinked
databases (http://www4.ncbi.nlm.nih.gov/Entrez/). Now the whole of
Medline is available on the site through an experimental
service, PubMed (http://www4.ncbi.nlm.nih.gov/PubMed/). In
PubMed retrieved citations are not only linked to related
articles or sequences, as in the Entrez databases, but there is
also a PreMedLine section, containing references to articles
that have not yet made it into the official Medline database
x You can even include hypertext links in your own web
documents to articles in PubMed (such as http://www4.ncbi.nlm.
nih.gov/htbin›post/Entrez/query?uid=8520280&form=6&db=m &Dopt=r) or,
more powerfully still, call up a whole swathe of related
articles in a single web address (try http://www4.ncbi.nlm.nih.gov/
htbin›post/Entrez/query?db=m&form=6&uid=8520280 &Dopt=m)
Kawasaki disease
x Following complaints on television that too many British
doctors are ignorant of Kawasaki disease, the Royal College
of General Practitioners has prepared a fact sheet (http://www.
rcgp.org.uk/news/rcn0009.htm), which is available on the RCGP’s
excellent web site (http://www.rcgp.org.uk/index.html)
x Those keen to know more about the aetiology of the
condition should consult an article by Nigel Curtis of
St Mary’s Medical School available on line on http://www.sm.ic.
ac.uk/paediatrics/kawa_cml.htm
x Support for families affected by the disease is available
from the Kawasaki Families’ Network (http://ourworld.
compuserve.com/homepages/kawasaki/). The network can also be
contacted by email on kawasaki@compuserve.com
Government information on the web
x If you tend to misfile or throw away the paper versions of
official government communications, don’t despair—you can
access government press releases on the Central Office of
Information’s web site (http://www.coi.gov.uk/coi/). Of particular
relevance here are the Department of Health’s press releases
(http://www.coi.gov.uk/coi/depts/GDH/GDH.html)
x The Department of Health itself has its own home page
(http://www.open.gov.uk/doh/dhhome.htm), nested within the
government information service (http://www.open.gov.uk/). On
the DoH home page you will find a search facility plus links
to DoH publications. Several mouse clicks down the line you
will find the full text of (so far) only one government white
paper on health (http://www.the›stationery›office.co.uk/publicat/bydoh.
htm), published by the newly privatised successor to HMSO,
the Stationery Office (http://www.the›stationery›office.co.uk)
Talking digital
x In his book Being Digital (see http://tulpi.interconnect.com.au/
∼pg/Negrop.htm for a review) Nicholas Negroponte envisages a
world where everyday devices are networked and have
enough intelligence to talk to one another, so that the
refrigerator can talk, say, to your car or to your toaster.
Perhaps one day your electrocardiograph will be able to talk
directly to the Cardiac Arrhythmia Advisory System (CAAS)
at the University of Oklahoma Health Sciences Center (http://
wailer.uokhsc.edu/einthoven.html). This expert system is able to
interpret and advise on electrocardiograms over the web.
According to its creators, its intended uses include decision
support for rural and non›specialist practitioners and
continuing medical education. Although still in
demonstration mode, CAAS will accept interesting
electrocardiograms for analysis in digital or in deadtree
format
x In a similar vein to CAAS is Hepaxpert (http://www.ping.at/
hepax/), a program that will interpret serology results for
hepatitis A and B over the web
x On a more technical level, communication between
medical imaging devices will be made easier by the launch
of a new standard for digital imaging and communications
in medicine, termed DICOM 3 (http://www.xray.hmc.psu.edu/
dicom/dicom_home.html). The new standard provides a detailed
specification for formatting and exchanging images between
imaging devices. For a tutorial on DICOM, particularly as
DICOM 3 relates to cardiology, see http://www.xray.hmc.psu.edu/
dicom/acc_tut/tutorial.html
E coli O157:H7 and meningococcal
meningitis
x The closing months of 1996 were marked in Britain by
outbreaks of E coli O157:H7 infection and meningococcal
meningitis. The Public Health Laboratory Service has
published online fact sheets about E coli O157:H7 on http://
www.open.gov.uk/cdsc/ecolifac.htm and about meningococcal
disease on http://www.open.gov.uk/cdsc/mengfact.htm
x Further information on E coli as a pathogen is available
from the E coli index at the University of Birmingham (http://
sun1.bham.ac.uk/bcm4ght6/res.html) and from the American Food
and Drug Administration’s Bad Bug Book (http://vm.cfsan.fda.
gov/∼mow/intro.html)
x Those keen to keep up to date with emerging infections
worldwide should visit the home page of the Program for
Monitoring Emerging Diseases (ProMED) on http://www.
healthnet.org/programs/promed.html and or join the ProMED
mailing list by sending an email with the message “subscribe
promed [your email address]” to majordomo@usa.
healthnet.org, leaving the subject line blank
Compiled by Mark Pallen
email m.pallen@ic.ac.uk
web page http://www.qmw.ac.uk/∼rhbm001/mpallen.html
If you are not yet on line you can find help in getting
connected in the ABC of Medical Computing (eds Nicholas
Lee and Andrew Millman, BMJ Publishing), which has
Mark Pallen’s Guide to the Internet as a supplement.
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